Publication: Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?
Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?
Date
Date
Date
Citations
Recher, M., Sahrbacher, U., Bremer, J., Arndt, B., Steiner, U., & Fontana, A. (2012). Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatology International, 32(2), 469–472. https://doi.org/10.1007/s00296-009-1290-z
Abstract
Abstract
Abstract
Inclusion body myositis (IBM), the most common inflammatory myopathy in the elderly, is often resistant to various forms of therapy. Placebo-controlled treatment trials with high dose intravenous immunoglobulins (IVIG) have shown disease amelioration in some but not all patients. Here, we present the informative case of a 70-year-old woman with diagnosed inclusion body myositis that showed progressive muscle weakness without treatment and following immuno-suppressive treatment with corticosteroids and azathioprine. A trial with low-do
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Recher, M
- Sahrbacher, U
- Bremer, J
- Arndt, B
- Steiner, U
- Fontana, A
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Metrics
Downloads
Views
Citations
Recher, M., Sahrbacher, U., Bremer, J., Arndt, B., Steiner, U., & Fontana, A. (2012). Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatology International, 32(2), 469–472. https://doi.org/10.1007/s00296-009-1290-z
